Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease

Experimental Neurology

Volumn 224, Issue 2, 2010, Pages 517-526

  Rodriguez Perez, Ana I ^a   Valenzuela, Rita ^a   Villar Cheda, Begoña ^a   Guerra, Maria J ^a   Lanciego, Jose L ^b   Labandeira Garcia, Jose L ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Angiotensin; Dopamine; Estrogen; Menopause; NADPH; Neuroinflammation; Neuroprotection; Parkinson; Replacement therapy

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; ESTRADIOL BENZOATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; HORMONE SUBSTITUTION; NEUROPROTECTION; NONHUMAN; OVARIECTOMY; PARKINSON DISEASE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SUBSTANTIA NIGRA; UPREGULATION;

ANGIOTENSIN II; ANIMALS; BENZIMIDAZOLES; CELL DEATH; DOPAMINE; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; NEUROGLIA; NEURONS; OVARIECTOMY; OXIDOPAMINE; PARKINSON DISEASE; PEPTIDYL-DIPEPTIDASE A; POSTMENOPAUSE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM; SUBSTANTIA NIGRA; TETRAZOLES;

EID: 77954658629     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.05.015     Document Type: Article

References (78)

1. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence. Nat. Med. 2004, 10:S18-S25.
2. Antonicelli R., Olivieri F., Morichi V., Urbani E., Mais V. Prevention of cardiovascular events in early menopause: a possible role for hormone replacement therapy. Int. J. Cardiol. 2008, 130:140-146.
3. Babior B. NADPH oxidase: An update. Blood 1999, 93:1464-1476.
4. Babior B.M. NADPH oxidase. Curr. Opin. Immunol. 2004, 16:42-47.
5. Benigni A., Corna D., Zoja C., Sonzogni A., Latini R., Salio M., Conti S., Rottoli D., Longaretti L., Cassis P., Morigi M., Coffman T.M., Remuzzi G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J. Clin. Invest. 2009, 119:524-530.
6. Bokil H.S., Porter J.P. Brain angiotensin type 1 receptor expression and function in the Zucker obese rat. Neurosci. Lett. 2000, 281:139-142.
7. Brown D.C., Steward L.J., Ge J., Barnes N.M. Ability of angiotensin II to modulate striatal dopamine release via AT1 receptor in vitro and in vivo. Brit. J. Pharmacol. 1996, 18:414-420.
8. Callier S., Le Saux M., Lhiaubet A.M., Di Paolo T., Rostène W., Pelaprat D. Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP+) towards dopaminergic mesencephalic neurones in primary culture. J. Neurochem. 2002, 80:307-316.
9. Coleman C.G., Anrather J., Iadecola C., Pickel V.M. Angiotensin II type 2 receptors have a major somatodendritic distribution in vasopressin-containing neurons in the mouse hypothalamic paraventricular nucleus. Neuroscience 2009, 163:129-142.
10. Cruz-Muros I., Afonso-Oramas D., Abreu P., Pérez-Delgado M.M., Rodríguez M., González-Hernández T. Aging effects on the dopamine transporter expression and compensatory mechanisms. Neurobiol. Aging 2009, 30:973-986.
11. Currie L.J., Harrison M.B., Trugman J.M., Bennett J.P., Wooten G.F. Postmenopausal estrogen use affects risk for Parkinson disease. Arch. Neurol. 2004, 61:886-888.
12. Dean S.A., Tan J., O'Brien E.R., Leenen F.H. 17beta-estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 288:R759-R766.
13. Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res. 1997, 767:340-344.
14. Dziuk P.J., Cook B. Passage of steroids through silicone rubber. Endocrinology 1966, 78:208-211.
15. Febo M., Ferris C.F., Segarra A.C. Estrogen influences cocaine-induced blood oxygen level-dependent signal changes in female rats. J. Neurosci. 2005, 25:1132-1136.
16. Franceschi C., Bonafè M., Valensin S., Olivieri F., De Luca M., Ottaviani E., De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci. 2000, 908:244-254.
17. Gao H.M., Liu B., Zhang W., Hong J.S. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinsońs disease. FASEB J. 2003, 17:1957-1959.
18. Griendling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 1994, 74:1141-1148.
19. Gundersen H.J.G., Bendsen T.F., Korbo L., Marcussen N., Moller A., Nielsen K. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APIMS 1988, 96:379-394.
20. Hemming M.L., Selkoe D.J., Farris W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease. Neurobiol. Dis. 2007, 26:273-281.
21. Hong H., Zeng J.S., Kreulen D.L., Kaufman D.I., Chen A.F. Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H2210-H2215.
22. Hoshi-Fukushima R., Nakamoto H., Imai H., Kanno Y., Ishida Y., Yamanouchi Y., Suzuki H. Estrogen and angiotensin II interactions determine cardio-renal damage in Dahl salt-sensitive rats with heart failure. Am. J. Nephrol. 2008, 28:413-423.
23. Joglar B., Rodriguez-Pallares J., Rodríguez-Perez A.I., Rey P., Guerra M.J., Labandeira-Garcia J.L. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J. Neurochem. 2009, 109:656-669.
24. Kannel W.B., Wilson P.W. Risk factors that attenuate the female coronary disease advantage. Arch. Intern. Med. 1995, 155:57-61.
25. Kehoe P.G., Miners K., Love S. Angiotensin in Alzheimer's disease - friend or foe?. Trends Neurosci. 2009, 32:619-628.
26. Kim M.J., Shin K.S., Chung Y.B., Jung K.W., Cha C.I., Shin D.H. Immunohistochemical study of p47Phox and gp91Phox distributions in the rat brain. Brain Res. 2005, 1040:178-186.
27. Krause E.G., Curtis K.S., Stincic T.L., Markle J.P., Contreras R.J. Oestrogen and weight loss decrease isoproterenol-induced Fos immunoreactivity and angiotensin type 1 mRNA in the subfornical organ of female rats. J. Physiol. 2006, 573:251-262.
28. Krishnamurthi K., Verbalis J.G., Zheng W., Wu Z., Clerch L.B., Sandberg K. Estrogen regulates angiotensin AT1 receptor expression via cytosolic proteins that bind to the 5' leader sequence of the receptor mRNA. Endocrinology 1999, 140:5435-5538.
29. Lazartigues E., Dunlay S.M., Loihl A.K., Sinnayah P., Lang J.A., Espelund J.J., Sigmund C.D., Davisson R.L. Brain-selective overexpression of angiotensin (AT1) receptors causes enhanced cardiovascular sensitivity in transgenic mice. Circ. Res. 2002, 90:617-624.
30. Leranth C., Roth R.H., Elsworth J.D., Naftolin F., Horvath T.L., Redmond D.E. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J. Neurosci. 2000, 20:8604-8609.
31. Lewis D.K., Johnson A.B., Stohlgren S., Harms A., Sohrabji F. Effects of estrogen receptor agonists on regulation of the inflammatory response in astrocytes from young adult and middle-aged female rats. J. Neuroimmunol. 2008, 195:47-59.
32. Li J.M., Shah A.M. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J. Biol. Chem. 2003, 278:12094-12100.
33. Liu H.W., Iwai M., Takeda-Matsubara Y., Wu L., Li J.M., Okumura M., Cui T.X., Horiuchi M. Effect of estrogen and AT1 receptor blocker on neointima formation. Hypertension 2002, 40:451-457.
34. Liu X., Fan X.L., Zhao Y., Luo G.R., Li X.P., Li R., Le W.D. Estrogen provides neuroprotection against activated microglia-induced dopaminergic neuronal injury through both estrogen receptor-alpha and estrogen receptor-beta in microglia. J. Neurosci. Res. 2005, 81:653-665.
35. Lopez-Real A., Rey P., Soto-Otero R., Mendez-Alvarez E., Labandeira-Garcia J.L. Angiotensin-converting enzyme inhibitors reduce oxidative stress and protect dopaminergic neurons in a 6-hydroxydopamine rat model of parkinsonism. J. Neurosci. Res. 2005, 81:865-873.
36. Lu D., Yang H., Shaw G., Raizada M.K. Angiotensin II-induced nuclear targeting of the angiotensin type 1 (AT1) receptor in brain neurons. Endocrinology 1998, 139:365-375.
37. Mannino C.A., South S.M., Inturrisi C.E., Quinones-Jenab V. Pharmacokinetics and effects of 17beta-estradiol and progesterone implants in ovariectomized rats. J. Pain 2005, 6:809-816.
38. McKinley M.J., Albiston A.L., Allen A.M., Mathai M.L., May C.N., McAllen R.M., Oldfield B.J., Mendelsohn F.A.O., Chai S. The brain reenin-angiotensin system: location and physiological roles. Int. J. Biochem. Cell Biol. 2003, 35:901-918.
39. Meissner W., Hill M.P., Tison F., Gross C.E., Bezard E. Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trends Pharmacol. Sci. 2004, 25:249-253.
40. Mertens B., Vanderheyden P., Michotte Y., Sarre S. The role of the central renin-angiotensin system in Parkinson's disease. J. Renin Angiotensin Aldosterone Syst. 2010, 11:49-56.
41. Mirza F.S., Ong P., Collins P., Okamura K., Gerhard-Herman M., Williams G.H., Seely E.W. Effects of estradiol and the angiotensin II receptor blocker irbesartan on vascular function in postmenopausal women. Menopause 2008, 15:44-50.
42. Morale M.C., Serra P.A., L'episcopo F., Tirolo C., Caniglia S., Testa N., Gennuso F., Giaquinta G., Rocchitta G., Desole M.S., Miele E., Marchetti B. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience 2006, 138:869-878.
43. Mosca L., Manson J.E., Sutherland S.E., Langer R.D., Manolio T., Barrett-Connor E. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. Circulation 1997, 96:2468-2482.
44. Muñoz A., Rey P., Guerra M.J., Mendez-Alvarez E., Soto-Otero R., Labandeira-Garcia J.L. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology 2006, 51:112-120.
45. Münzel T., Keany J.F. Are ACE inhibitors a "magic bullet" against oxidative stress?. Circulation 2001, 104:1571-1577.
46. Naftolin F., Schneider H.P., Sturdee D.W. Executive Committee of the International Menopause Society. Guidelines for hormone treatment of women in the menopausal transition and beyond. Maturitas 2005, 51:15-20.
47. Nishimura Y., Ito T., Hoe K., Saavedra J.M. Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors. Brain Res. 2000, 871:29-38.
48. Nogawa N., Sumino H., Ichikawa S., Kumakura H., Takayama Y., Nakamura T., Kanda T., Mizunuma H., Kurabayashi M. Effect of long-term hormone replacement therapy on angiotensin-converting enzyme activity and bradykinin in postmenopausal women with essential hypertension and normotensive postmenopausal women. Menopause 2001, 8:210-215.
49. Obermüller N., Gentili M., Gauer S., Gretz N., Weigel M., Geiger H., Gassler N. Immunohistochemical and mRNA localization of the angiotensin II receptor subtype 2 (AT2) in follicular granulosa cells of the rat ovary. J. Histochem. Cytochem. 2004, 52:545-548.
50. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1986, Academic Press, New York.
51. Phillips M.I., Kagiyama S. Angiotensin II as a pro-inflammatory mediator. Curr. Opin. Investig. Drugs. 2002, 3:569-577.
52. Pines A., Sturdee D.W., Birkhauser M.H., de Villiers T., Naftolin F., Gompel A., Farmer R., Barlow D., Tan D., Maki P., Lobo R., Hodis H. HRT in the early menopause: scientific evidence and common perceptions. Climacteric 2008, 11:267-272. International Menopause Society.
53. Popat R.A., Van Den Eeden S.K., Tanner C.M., McGuire V., Bernstein A.L., Bloch D.A., Leimpeter A., Nelson L.M. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 2005, 65:383-390.
54. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., Togasaki D.M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 1995, 67:631-647.
55. Qin L., Liu Y., Wang T., Wei S.J., Block M.L., Wilson B., Liu B., Hong J.S. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J. Biol. Chem. 2004, 279:1415-1421.
56. Ragonese P., D'Amelio M., Callari G., Salemi G., Morgante L., Savettieri G. Age at menopause predicts age at onset of Parkinson's disease. Mov. Disord. 2006, 21:2211-2214.
57. Ragonese P., D'Amelio M., Savettieri G. Implications for estrogens in Parkinson's disease: an epidemiological approach. Ann. N. Y. Acad. Sci. 2006, 1089:373-382.
58. Rey P., Lopez-Real A., Sanchez-Iglesias S., Muñoz A., Soto-Otero R., Labandeira-Garcia J.L. Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol. Aging 2007, 28:555-567.
59. Rodriguez-Pallares J., Parga J.A., Muñoz A., Rey P., Guerra M.J., Labandeira-Garcia J.L. Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J. Neurochem. 2007, 103:145-156.
60. Rodriguez-Pallares J., Rey P., Parga J.A., Muñoz A., Guerra M.J., Labandeira-Garcia J.L. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol. Dis. 2008, 31:58-73.
61. Ruiz-Ortega M., Lorenzo O., Ruperez M., Esteban V., Suzuki Y., Mezzano S., Plaza J.J., Egido J. Role of the renin-angiotensin system in vascular diseases. Expanding the field. Hypertension 2001, 38:1382-1387.
62. Ruiz-Ortega M., Esteban V., Suzuki Y., Ruperez M., Mezzano S., Ardiles L., Justo P., Ortiz A., Egido J. Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. Kidney Int. Suppl. 2003, 86:S21-S26.
63. Saavedra J.M. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell. Mol. Neurobiol. 2005, 25:485-512.
64. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunohistochemical study in the rat. Neuroscience 1994, 59:401-415.
65. Shekhar A., Johnson P.L., Sajdyk T.J., Fitz S.D., Keim S.R., Kelley P.E., Gehlert D.R., DiMicco J.A. Angiotensin-II is a putative neurotransmitter in lactate-induced panic-like responses in rats with disruption of GABAergic inhibition in the dorsomedial hypothalamus. J. Neurosci. 2006, 26:9205-9215.
66. Shulman L.M. Is there a connection between estrogen and Parkinson's disease?. Parkinsonism Relat. Disord. 2002, 8:289-295.
67. Sohn H.Y., Raff U., Hoffmann A., Gloe T., Heermeier K., Galle J., Pohl U. Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br. J. Pharmacol. 2000, 131:667-672.
68. Touyz R.M., Chen X., Tabet F., Yao G., He G., Quinn M.T., Pagano P.J., Schiffrin E.L. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ. Res. 2002, 14:1205-1213.
69. Tripanichkul W., Sripanichkulchai K., Finkelstein D.I. Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine intoxication. Brain Res. 2006, 1084:28-37.
70. Tsuda M., Iwai M., Li J.M., Li H.S., Min L.J., Ide A., Okumura M., Suzuki J., Mogi M., Suzuki H., Horiuchi M. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 2005, 45:545-551.
71. Unger T. Inhibiting angiotensin receptors in the brain: possible therapeutic implications. Curr. Med. Res. Opin. 2003, 19:449-451.
72. Villar-Cheda B., Sousa-Ribeiro D., Rodriguez-Pallares J., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Aging and sedentarism decrease vascularization and VEGF levels in the rat substantia nigra. Implications for Parkinson's disease. J. Cereb. Blood Flow Metab. 2009, 29:230-234.
73. Wang G., Anrather J., Huang J., Speth R.C., Pickel V.M., Iadecola C. NADPH oxidase contributes to angiotensin II signaling in the nucleus tractus solitarius. J. Neurosci. 2004, 24:5516-5524.
74. Warnholtz A., Münzel T. Why do antioxidants fail to provide clinical benefit?. Curr. Control Trials Cardiovasc. Med. 2000, 1:38-40.
75. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 2002, 22:1763-1771.
76. Wu D., Teisman P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., Przedborski S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson̈s disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6145-6150.
77. Wu Z., Zheng W., Sandberg K. Estrogen regulates adrenal angiotensin type 1 receptors by modulating adrenal angiotensin levels. Endocrinology 2003, 144:1350-1356.
78. Xue B., Pamidimukkala J., Lubahn D.B., Hay M. Estrogen receptor-alpha mediates estrogen protection from angiotensin II-induced hypertension in conscious female mice. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H1770-H1776.